Curie Oncology partners up with Oncoshot to deploy AI in improving patient outcomes in Asia, makes strategic investment into the company

Curie Oncology, one of Southeast Asia’s fastest growing private oncology networks that runs numerous clinical trials across Singapore and Malaysia, has partnered with Singapore-based healthtech company Oncoshot to deploy AI-powered clinical research tools that can rapidly structure and analyse clinical data, enabling oncologists and research teams to identify eligible patients sooner and help patients gain faster access to ongoing clinical trials more efficiently.  

AI as an enabler

Oncoshot’s platform functions as a secure, behind-the-scenes engine that converts unstructured oncology documents into research-ready datasets. During this rollout, the AI system will be used to

• Extract and de-identify data with >95% accuracy, even with varied source systems

• Allow research coordinators to spend more time on patient-facing and trail-critical tasks, instead of repetitive data processing

Oncoshot's role is to support, not replace, Curie's clinical research processes. The AI system helps teams screen faster, run feasibility checks more consistently, and scale their research programmes without requiring proportional increases in manpower.

Strong partnerships across the Oncoshot ecosystem

Curie Oncology is among the first private oncology networks in Asia to deploy Oncoshot's AI platform, extending the company's work with earlier public-facing collaborations across Singapore's cancer research ecosystem.

This includes earlier collaborations such as the 2022 project with Icon Cancer Centre and Roche to digitise genomic data, a workflow that has since been fully automated, as well as deployments with Tan Tock Seng Hospital and the National Cancer Centre Singapore which were highlighted in presentations at the International Association of Cancer Registries (IACR) 2025.

Together, these implementations illustrate how AI can support both public and private cancer institutions in processing unstructured oncology data securely and efficiently. Oncoshot's federated architecture ensures that raw patient data remains within each institution's environment, while maintaining compliance with HIPAA, GDPR, and Singapore PDPC regulations.

Curie Oncology has also made an undisclosed private investment into Oncoshot, further strengthening their burgeoning partnership in digitalizing the clinical landscape in Asia.

About Milltrust Ventures

Milltrust Ventures has been a continued supporter of Oncoshot’s groundbreaking AI work since our first investment (alongside Seeds Capital (rebranded as SG Growth Capital) and Lion City Capital) into the company in 2022 via our third VC fund, the Future Health Fund. This follows on from our decades-long venture capital work from the successfully-exited British Innovation Fund and CerraCap Ventures II.

For anyone that wishes to learn more about our strong body of work in private markets investments and participate alongside us in our enterprising journey (investing in the 3 defining themes of human health, food security, and sustainability), we welcome the chance to discuss the opportunity further. Please get in touch via mv@milltrust.com.